These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 39200298)

  • 1. Oncolytic Tanapoxvirus Variants Expressing mIL-2 and mCCL-2 Regress Human Pancreatic Cancer Xenografts in Nude Mice.
    Haller SD; Essani K
    Biomedicines; 2024 Aug; 12(8):. PubMed ID: 39200298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-independent response mediated by oncolytic tanapoxvirus recombinants expressing interleukin-2 and monocyte chemoattractant protein-1 suppresses human triple negative breast tumors.
    Suryawanashi YR; Zhang T; Woyczesczyk HM; Christie J; Byers E; Kohler S; Eversole R; Mackenzie C; Essani K
    Med Oncol; 2017 Jun; 34(6):112. PubMed ID: 28466296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Administration Routes, Including Intramuscular Injection, of Oncolytic Tanapoxvirus Variants Significantly Regress Human Melanoma Xenografts in BALB/c Nude Mice Reconstituted with Splenocytes from Normal BALB/c Donors.
    Monaco ML; Idris OA; Filpi GA; Kohler SL; Haller SD; Burr JE; Eversole R; Essani K
    Genes (Basel); 2023 Jul; 14(8):. PubMed ID: 37628585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic Tanapoxvirus Recombinants Expressing Flagellin C or Mouse Interleukin-2 Are Capable of Regressing Human Triple-Negative Breast Cancer Xenografts in Immuno-Competent BALB/c Nude Mice.
    Monaco ML; Filpi GA; Kohler SL; Eversole R; Idris OA; Essani K
    Pathogens; 2024 May; 13(5):. PubMed ID: 38787254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic tanapoxvirus expressing FliC causes regression of human colorectal cancer xenografts in nude mice.
    Conrad SJ; El-Aswad M; Kurban E; Jeng D; Tripp BC; Nutting C; Eversole R; Mackenzie C; Essani K
    J Exp Clin Cancer Res; 2015 Feb; 34(1):19. PubMed ID: 25887490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic Tanapoxvirus Expressing Interleukin-2 is Capable of Inducing the Regression of Human Melanoma Tumors in the Absence of T Cells.
    Zhang T; Kordish DH; Suryawanshi YR; Eversole RR; Kohler S; Mackenzie CD; Essani K
    Curr Cancer Drug Targets; 2018; 18(6):577-591. PubMed ID: 28669340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tanapoxvirus lacking a neuregulin-like gene regresses human melanoma tumors in nude mice.
    Zhang T; Suryawanshi YR; Kordish DH; Woyczesczyk HM; Jeng D; Essani K
    Virus Genes; 2017 Feb; 53(1):52-62. PubMed ID: 27738905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer.
    Haller SD; Monaco ML; Essani K
    Viruses; 2020 Nov; 12(11):. PubMed ID: 33213031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tanapoxvirus lacking the 15L gene inhibits melanoma cell growth in vitro by inducing interferon-λ1 release.
    Zhang T; Essani K
    Virus Genes; 2017 Jun; 53(3):477-482. PubMed ID: 28188458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intertumoral heterogeneity impacts oncolytic vesicular stomatitis virus efficacy in mouse pancreatic cancer cells.
    Goad DW; Nesmelova AY; Yohe LR; Grdzelishvili VZ
    J Virol; 2023 Sep; 97(9):e0100523. PubMed ID: 37671865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures.
    Schäfer TE; Knol LI; Haas FV; Hartley A; Pernickel SCS; Jády A; Finkbeiner MSC; Achberger J; Arelaki S; Modic Ž; Schröer K; Zhang W; Schmidt B; Schuster P; Haferkamp S; Doerner J; Gebauer F; Ackermann M; Kvasnicka HM; Kulkarni A; Bots STF; Kemp V; Hawinkels LJAC; Poetsch AR; Hoeben RC; Ehrhardt A; Marchini A; Ungerechts G; Ball CR; Engeland CE
    EBioMedicine; 2024 Jul; 105():105219. PubMed ID: 38941955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. OX40L-Armed Oncolytic Virus Boosts T-cell Response and Remodels Tumor Microenvironment for Pancreatic Cancer Treatment.
    Liu S; Li F; Ma Q; Du M; Wang H; Zhu Y; Deng L; Gao W; Wang C; Liu Y; Zhao Z; Liu H; Wang R; Tian Y; Hu M; Wan Y; Lu W; Zhang M; Zhao M; Cao Y; Zhang H; Wang W; Wang H; Wang Y
    Theranostics; 2023; 13(12):4016-4029. PubMed ID: 37554264
    [No Abstract]   [Full Text] [Related]  

  • 13. Oncolytic Adenovirus Expressing ST13 Increases Antitumor Effect of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Against Pancreatic Ductal Adenocarcinoma.
    Zhang Y; Ye M; Huang F; Wang S; Wang H; Mou X; Wang Y
    Hum Gene Ther; 2020 Aug; 31(15-16):891-903. PubMed ID: 32475172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural killer T cell immunotherapy combined with IL-15-expressing oncolytic virotherapy and PD-1 blockade mediates pancreatic tumor regression.
    Nelson A; Gebremeskel S; Lichty BD; Johnston B
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35246474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40L-armed oncolytic herpes simplex virus suppresses pancreatic ductal adenocarcinoma by facilitating the tumor microenvironment favorable to cytotoxic T cell response in the syngeneic mouse model.
    Wang R; Chen J; Wang W; Zhao Z; Wang H; Liu S; Li F; Wan Y; Yin J; Wang R; Li Y; Zhang C; Zhang H; Cao Y
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35086948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experimental Evolution Generates Novel Oncolytic Vesicular Stomatitis Viruses with Improved Replication in Virus-Resistant Pancreatic Cancer Cells.
    Seegers SL; Frasier C; Greene S; Nesmelova IV; Grdzelishvili VZ
    J Virol; 2020 Jan; 94(3):. PubMed ID: 31694943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.
    Felt SA; Droby GN; Grdzelishvili VZ
    J Virol; 2017 Aug; 91(16):. PubMed ID: 28566376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer.
    Araki H; Tazawa H; Kanaya N; Kajiwara Y; Yamada M; Hashimoto M; Kikuchi S; Kuroda S; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
    Mol Ther Oncolytics; 2022 Dec; 27():3-13. PubMed ID: 36212775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer.
    Kajiwara Y; Tazawa H; Yamada M; Kanaya N; Fushimi T; Kikuchi S; Kuroda S; Ohara T; Noma K; Yoshida R; Umeda Y; Urata Y; Kagawa S; Fujiwara T
    Cancer Immunol Immunother; 2023 May; 72(5):1285-1300. PubMed ID: 36436021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virotherapy using a novel chimeric oncolytic adenovirus prolongs survival in a human pancreatic cancer xenograft model.
    Chu QD; Sun G; Pope M; Luraguiz N; Curiel DT; Kim R; Li BD; Mathis JM
    Surgery; 2012 Sep; 152(3):441-8. PubMed ID: 22853858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.